Achieve Life Sciences Stock Price, News & Analysis (NASDAQ:ACHV)

$1.46 -0.05 (-3.31 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$1.46
Today's Range$1.43 - $1.58
52-Week Range$1.15 - $7.15
Volume457,472 shs
Average Volume624,733 shs
Market Capitalization$16.97 million
P/E Ratio-0.28
Dividend YieldN/A
Beta2.01

About Achieve Life Sciences (NASDAQ:ACHV)

Achieve Life Sciences logoAchieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Cytisine and OGX-225. These products are designed to block the production of specific proteins that promotes treatment resistance and survival of tumor cells, and are over-produced in response to a variety of cancer treatments. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies.

Receive ACHV News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACHV
CUSIP68230A10
Phone425-686-1500

Debt

Debt-to-Equity RatioN/A
Current Ratio3.70%
Quick Ratio3.70%

Price-To-Earnings

Trailing P/E Ratio-0.275450389686836
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.06 million
Price / Sales3.45
Cash FlowN/A
Price / CashN/A
Book Value$6.95 per share
Price / Book0.21

Profitability

Trailing EPS($5.30)
Net Income$-20,120,000.00
Net MarginsN/A
Return on Equity-126.78%
Return on Assets-101.46%

Miscellaneous

Employees17
Outstanding Shares11,950,000

Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences Inc (NASDAQ:ACHV) posted its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter. View Achieve Life Sciences' Earnings History.

When will Achieve Life Sciences make its next earnings announcement?

Achieve Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Achieve Life Sciences.

Who are some of Achieve Life Sciences' key competitors?

Who are Achieve Life Sciences' key executives?

Achieve Life Sciences' management team includes the folowing people:

  • Richard Stewart, Chairman of the Board, Chief Executive Officer (Age 58)
  • Anthony Clarke, President, Chief Scientific Officer, Director (Age 61)
  • John A. Bencich, Chief Financial Officer, Chief Operating Officer, Executive Vice President (Age 39)
  • Cindy Jacobs M.D., Ph.D., Executive Vice President, Chief Medical Officer (Age 59)
  • Donald Joseph, Independent Director (Age 62)
  • Martin A. Mattingly Ph.D., Independent Director (Age 60)
  • Jay Moyes, Independent Director (Age 62)
  • H. Stewart Parker, Independent Director (Age 61)

Who owns Achieve Life Sciences stock?

Achieve Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.36%). Company insiders that own Achieve Life Sciences stock include Cindy Jacobs, John Bencich and Scott Daniel Cormack. View Institutional Ownership Trends for Achieve Life Sciences.

Who bought Achieve Life Sciences stock? Who is buying Achieve Life Sciences stock?

Achieve Life Sciences' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Achieve Life Sciences.

How do I buy Achieve Life Sciences stock?

Shares of Achieve Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achieve Life Sciences' stock price today?

One share of Achieve Life Sciences stock can currently be purchased for approximately $1.46.

How big of a company is Achieve Life Sciences?

Achieve Life Sciences has a market capitalization of $16.97 million and generates $5.06 million in revenue each year. The biopharmaceutical company earns $-20,120,000.00 in net income (profit) each year or ($5.30) on an earnings per share basis. Achieve Life Sciences employs 17 workers across the globe.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 19820 NORTH CREEK PARKWAY, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-686-1500 or via email at [email protected]


MarketBeat Community Rating for Achieve Life Sciences (ACHV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about Achieve Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Achieve Life Sciences (NASDAQ:ACHV) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Achieve Life Sciences (NASDAQ:ACHV) Earnings History and Estimates Chart

Earnings by Quarter for Achieve Life Sciences (NASDAQ:ACHV)

Achieve Life Sciences (NASDAQ ACHV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018        
11/9/2017Q3 2017($0.90)ViewN/AView Earnings Details
7/31/2017Q2 2017($0.10)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.29)($0.11)ViewN/AView Earnings Details
2/23/2017Q4 2016($2.09)ViewN/AView Earnings Details
11/10/2016Q316($0.26)($0.12)ViewN/AView Earnings Details
8/4/2016Q216($0.22)($0.23)$1.17 million$2.10 millionViewN/AView Earnings Details
5/12/2016Q116($0.12)($0.12)$4.09 million$2.90 millionViewListenView Earnings Details
3/9/2016Q4($0.15)($0.06)$6.00 million$6.02 millionViewN/AView Earnings Details
11/12/2015Q3($0.17)($0.16)$5.97 million$6.74 millionViewListenView Earnings Details
8/13/2015Q2$0.34($0.26)$16.10 million$4.03 millionViewListenView Earnings Details
5/14/2015Q115($0.34)($0.20)$4.66 million$1.40 millionViewListenView Earnings Details
3/26/2015Q414($0.30)($0.27)$4.30 million$5.70 millionViewN/AView Earnings Details
10/30/2014($0.38)($0.23)$4.69 million$4.80 millionViewN/AView Earnings Details
8/7/2014($0.55)($0.47)$11.73 million$4.93 millionViewN/AView Earnings Details
4/30/2014($0.50)($0.59)$8.68 million$11.73 millionViewN/AView Earnings Details
3/11/2014Q113($0.66)($0.45)$10.20 million$8.60 millionViewN/AView Earnings Details
11/7/2013Q3 2013($7.59)($7.48)$6.67 million$9.86 millionViewN/AView Earnings Details
8/8/2013Q2 2013($6.93)($6.27)$5.97 million$6.34 millionViewN/AView Earnings Details
5/2/2013Q1 2013($7.48)($6.16)$5.28 million$5.08 millionViewN/AView Earnings Details
3/7/2013Q4 2012($5.39)($4.29)ViewN/AView Earnings Details
11/8/2012Q312($0.49)($0.40)$4.52 million$6.57 millionViewN/AView Earnings Details
8/2/2012Q2 2012($5.94)($3.19)ViewN/AView Earnings Details
5/3/2012Q1 2012($7.59)($5.86)ViewN/AView Earnings Details
3/8/2012Q4 2011($6.49)($10.79)ViewN/AView Earnings Details
11/3/2011Q3 2011($5.94)($4.90)ViewN/AView Earnings Details
8/4/2011Q2 2011($6.05)($7.39)ViewN/AView Earnings Details
5/9/2011Q1 2011($4.95)($5.82)ViewN/AView Earnings Details
3/10/2011Q4 2010($5.28)$3.45ViewN/AView Earnings Details
11/4/2010Q3 2010($5.17)($11.75)ViewN/AView Earnings Details
8/5/2010Q2 2010($4.95)($4.80)ViewN/AView Earnings Details
5/6/2010Q1 2010($4.95)($5.29)ViewN/AView Earnings Details
3/8/2010Q4 2009$2.09($7.04)ViewN/AView Earnings Details
11/5/2009Q3 2009($6.60)($4.35)ViewN/AView Earnings Details
8/6/2009Q2 2009($6.05)($9.04)ViewN/AView Earnings Details
5/7/2009Q1 2009($4.77)ViewN/AView Earnings Details
3/11/2009Q4 2008($10.89)ViewN/AView Earnings Details
11/10/2008Q3 2008$0.78ViewN/AView Earnings Details
3/5/2008Q4 2007($53.42)$10.29ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Achieve Life Sciences (NASDAQ:ACHV) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Achieve Life Sciences (NASDAQ:ACHV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Achieve Life Sciences (NASDAQ ACHV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.80%
Institutional Ownership Percentage: 3.49%
Insider Trades by Quarter for Achieve Life Sciences (NASDAQ:ACHV)

Achieve Life Sciences (NASDAQ ACHV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2016John BencichCFOSell1,380$0.57$786.605,000View SEC Filing  
6/13/2016Cindy JacobsCMOSell1,437$1.03$1,480.1178,853View SEC Filing  
6/13/2016Scott Daniel CormackCEOSell4,856$1.03$5,001.68134,284View SEC Filing  
3/15/2016Cindy JacobsCMOSell3,254$0.83$2,700.8277,107View SEC Filing  
3/15/2016John BencichCFOSell834$0.83$692.226,698View SEC Filing  
3/15/2016Scott Daniel CormackCEOSell12,033$0.83$9,987.39136,942View SEC Filing  
8/18/2015John BencichCFOSell1,427$2.76$3,938.523,573View SEC Filing  
6/12/2015Cindy JacobsCMOSell1,408$2.69$3,787.52View SEC Filing  
6/12/2015Scott Daniel CormackCEOSell4,571$2.69$12,295.99View SEC Filing  
5/20/2015Cindy JacobsCMOSell2,092$1.88$3,932.96View SEC Filing  
5/20/2015Scott Daniel CormackCEOSell7,543$1.88$14,180.84View SEC Filing  
8/13/2014Cindy JacobsCMOSell5,650$3.17$17,910.50View SEC Filing  
8/13/2014Scott Daniel CormackCEOSell18,341$3.17$58,140.97View SEC Filing  
3/17/2014Cindy JacobsCMOSell1,250$12.25$15,312.5028,905View SEC Filing  
3/17/2014Scott Daniel CormackCEOSell4,634$12.25$56,766.5064,980View SEC Filing  
8/19/2013Cindy JacobsCMOSell1,364$8.68$11,839.5225,780View SEC Filing  
8/19/2013Scott Daniel CormackCEOSell3,112$8.68$27,012.1660,238View SEC Filing  
3/12/2013Scott Daniel CormackCEOSell2,134$11.90$25,394.6056,788View SEC Filing  
8/15/2012Jack GoldsteinDirectorBuy1,000$14.38$14,380.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Achieve Life Sciences (NASDAQ ACHV) News Headlines

Source:
DateHeadline
meltmedia Achieves Acquia Foundation Plus Partner Statusmeltmedia Achieves Acquia Foundation Plus Partner Status
www.bizjournals.com - February 20 at 5:47 PM
Achieve Life Sciences cytisine shows encouraging effect in smoking cessation study; shares up 54%Achieve Life Sciences' cytisine shows encouraging effect in smoking cessation study; shares up 54%
seekingalpha.com - February 20 at 5:47 PM
Here’s Why Achieve Life Sciences Inc (ACHV) Jumped as Much as 54% TodayHere’s Why Achieve Life Sciences Inc (ACHV) Jumped as Much as 54% Today
finance.yahoo.com - February 20 at 5:47 PM
Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical StudyAchieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
finance.yahoo.com - February 20 at 8:16 AM
Global Host Cell Contaminant Testing Market to Reach US$ 354 Mn by 2025 - Persistence Market ResearchGlobal Host Cell Contaminant Testing Market to Reach US$ 354 Mn by 2025 - Persistence Market Research
www.prnewswire.com - February 19 at 5:10 PM
Innovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth PlansInnovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth Plans
finance.yahoo.com - February 13 at 9:49 AM
A Traders View On Why Bigger Is (Usually) BetterA Trader's View On Why Bigger Is (Usually) Better
finance.yahoo.com - February 2 at 3:47 PM
Achieve Life Sciences Making Progress in the Smoking Cessation Market, Recent EventsAchieve Life Sciences Making Progress in the Smoking Cessation Market, Recent Events
finance.yahoo.com - January 26 at 9:08 AM
What Does Achieve Life Sciences Inc’s (NASDAQ:ACHV) Ownership Structure Look Like?What Does Achieve Life Sciences Inc’s (NASDAQ:ACHV) Ownership Structure Look Like?
finance.yahoo.com - January 24 at 8:07 AM
Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic CategoriesAchieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
finance.yahoo.com - January 24 at 8:07 AM
A Look At Achieve Life Sciences Inc (NASDAQ:ACHV) And The Healthcare SectorA Look At Achieve Life Sciences Inc (NASDAQ:ACHV) And The Healthcare Sector
finance.yahoo.com - January 2 at 7:34 PM
Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking CessationAchieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation
finance.yahoo.com - December 7 at 6:28 PM
ValuEngine Upgrades OncoGenex Pharmaceuticals (ACHV) to SellValuEngine Upgrades OncoGenex Pharmaceuticals (ACHV) to Sell
www.americanbankingnews.com - December 4 at 11:10 PM
OncoGenex Pharmaceuticals Inc. (ACHV) Announces  Earnings ResultsOncoGenex Pharmaceuticals Inc. (ACHV) Announces Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM
Critical Survey: OncoGenex Pharmaceuticals (ACHV) & The CompetitionCritical Survey: OncoGenex Pharmaceuticals (ACHV) & The Competition
www.americanbankingnews.com - November 10 at 3:10 AM
Achieve Reports Financial Results for Third Quarter 2017Achieve Reports Financial Results for Third Quarter 2017
finance.yahoo.com - November 9 at 4:24 PM
Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017
finance.yahoo.com - November 8 at 5:23 PM
Achieve Announces Availability of Company Presentation from the Virtual Investor ConferenceAchieve Announces Availability of Company Presentation from the Virtual Investor Conference
finance.yahoo.com - November 6 at 4:09 PM
Financial Contrast: OncoGenex Pharmaceuticals (ACHV) and The CompetitionFinancial Contrast: OncoGenex Pharmaceuticals (ACHV) and The Competition
www.americanbankingnews.com - November 3 at 1:10 PM
Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017
finance.yahoo.com - October 30 at 3:29 PM
Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of CytisineAchieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
finance.yahoo.com - October 26 at 11:35 AM
CASI Pharmaceuticals (CASI) and OncoGenex Pharmaceuticals (ACHV) Critical ReviewCASI Pharmaceuticals (CASI) and OncoGenex Pharmaceuticals (ACHV) Critical Review
www.americanbankingnews.com - October 26 at 1:16 AM
Head to Head Review: OncoGenex Pharmaceuticals (ACHV) & The CompetitionHead to Head Review: OncoGenex Pharmaceuticals (ACHV) & The Competition
www.americanbankingnews.com - October 24 at 12:30 PM
Achieve Announces Advancement of Cytisine Clinical Development ProgramAchieve Announces Advancement of Cytisine Clinical Development Program
finance.yahoo.com - October 4 at 8:09 AM
BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2017 AGM and Awards Gala - Business Wire (press release)BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2017 AGM and Awards Gala - Business Wire (press release)
www.businesswire.com - September 23 at 8:40 PM
Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLCAchieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
finance.yahoo.com - September 14 at 8:24 PM
Achieve Announces Initiation of Cytisine Clinical Development ProgramAchieve Announces Initiation of Cytisine Clinical Development Program
finance.yahoo.com - August 16 at 3:24 PM
Albany Molecular Research (AMRI) & OncoGenex Pharmaceuticals (ACHV) Critical ComparisonAlbany Molecular Research (AMRI) & OncoGenex Pharmaceuticals (ACHV) Critical Comparison
www.americanbankingnews.com - August 15 at 6:08 PM
Achieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation TreatmentAchieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment
finance.yahoo.com - August 10 at 4:51 PM
Affirmative Action Battle Has a New Focus: Asian-Americans - The ... - New York TimesAffirmative Action Battle Has a New Focus: Asian-Americans - The ... - New York Times
www.nytimes.com - August 4 at 12:47 PM

SEC Filings

Achieve Life Sciences (NASDAQ:ACHV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Achieve Life Sciences (NASDAQ:ACHV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Achieve Life Sciences (NASDAQ ACHV) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.